Activity in Medical Technology

Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC

CALGARY, July 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) ('Oncolytics') reported today that Dr. Shizuko Sei et al. published the results of their work examining reovirus and chemotherapy against human non-small cell lung cancer (NSCLC). The paper, entitled "Syn...

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients

Clinical Data Presented at the 2009 ASCO Meeting INDIANAPOLIS, May 30 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today presented data from a Phase I clinical trial of its vascular targeted pan-PI3K/mTORC1/2 inhibitor, SF1126...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

KRX-0401 Demonstrates Impressive Single Agent Efficacy in Patients who Progressed after Failing Treatment Either with a VEGF Receptor Inhibitor or after Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor NEW YORK, May 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, I...

New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer

COLLEGEVILLE, Pa., May 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) bre...

Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections

A Drug's Activity Against Anaerobes is the Leading Attribute in Antibiotic Selection, According to a New Report from AMR and Decision Resources MALVERN, Pa. and WALTHAM, Mass. , May 27 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that surveyed physicians will...

Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia

-- Data Presented at American Urological Association Annual Meeting -- SEATTLE and CHICAGO, April 28 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN ) today presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small m...

ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients

Data Being Presented Today at 44th Annual Meeting of EASL Management to Discuss Study Results and Program Status During Q1 Financial Results Call at 5 P.M. EDT Today SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced that ANA598,...

Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model

-Preclinical Results Further Validate Significant Anti-Tumor Potential of Fully Human Anti-PS Antibodies and Expand the Company's PS-Targeting Platform- -Treatment with Mouse Equivalent to the Human Antibody Inhibited Tumor Growth in a Prostate Cancer Model by More than 90%- DE...

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells

Study Presented at 2009 AACR Meeting Highlights Potential Therapeutic Approach to Treat Patients Unresponsive to Erbitux and Vectibix DENVER, April 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treat...

Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer

- Data Presented at the American Association for Cancer Research - PRINCETON, N.J., April 21 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced preclinical efficacy and safety data from multiple programs, including antibodies to novel and potentially important cancer ta...

ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients

Patients treated at the initial dose in an ongoing Phase Ib trial demonstrated a 2.5 log10 median viral load decline after three days Conference Call Today at 8:30AM EST SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced results fr...

Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference

CAMBRIDGE, Mass., Jan. 6 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the company has recently completed a successful toxicology study of its candidate CEQ501, an orally a...

New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia

US Oncology Affiliated Physicians Participate in ASH Conference SAN FRANCISCO, Dec. 8 /PRNewswire/ -- A leading cancer researcher affiliated with the US Oncology Research Network will present findings from a randomized, multicenter Phase III trial that compared FCR and PCR in patients wit...

Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma

PRINCETON, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) announced today results from a preclinical study for MDX-1401, a second-generation non-fucosylated version of MDX-060 that targets CD30, a marker for activated lymphocytes that is present on the malignant cells of Ho...

Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells

BETHESDA, Md., Nov. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented data from a preclinical study(1) showing cytotoxic activity of anti-E...

CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma

- Data presented at the 2008 iSBTc Annual Meeting - - Conference call to be hosted today at 11:00 a.m. ET to discuss results - BRANFORD, Conn., Nov. 3 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ) announced today preliminary data from an ongoing Phase II trial of CR011-vcMM...

Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus

Encouraging Clinical Data Presented at American College of Rheumatology (ACR) meeting Show Reduced Need for Concomitant Corticosteroid Therapy SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- UCB (Euronext Brussels: UCB) announced data from two randomized controlled trials showing that treat...

Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA

EDP-322 is a First-in-class MRSA-active Bicyclolide, a novel macrolide-related drug class WATERTOWN, Mass., Sept. 15 /PRNewswire/ -- Enanta Pharmaceuticals, a leader in the development of small molecule anti-infective drugs, announced today the initiation of a Phase ...

Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer

EAST SETAUKET, N.Y., Aug. 8 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today that lead compounds from each of two different types of drugs being developed as potential treatment for specific types of brain cancers have activity against hum...

Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference

MEXICO CITY and SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ) today announced that data was presented from its completed Phase 2a proof-of-concept monotherapy study of RDEA806, the Company's novel investigational non-nucleoside reverse transcriptase inhib...

Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia

Compound Inhibits Mutant Forms of BCR-ABL That Cause Resistance to Current CML and ALL Therapies COPENHAGEN, Denmark, June 13 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL ) today reported preliminary phase 1 data from an ongoing trial of XL228 in patients with...

Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients

CAMBRIDGE, Mass., June 12 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported phase I/II data for IDX899, a non-nucl...

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

Data Presented at ASCO Show 26% Partial Response, 63% Clinical Benefit Incidence HAYWARD, Calif., June 3 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that its lead Hsp90 inhibitor, tanespimycin, demonstrated a high lev...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois

Phase 2 Results of Perifosine in the Treatment of Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia to be presented Tomorrow, Tuesday, June 3rd at 12:00pm in Room E450a NEW YORK, June 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) toda...

CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma

- Data presented at the 2008 ASCO Annual Meeting - - Conference call to be hosted Wednesday, June 4 at 9:00 a.m. EDT to discuss results - BRANFORD, Conn., June 1 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ) today presented encouraging res...

Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)

SAN MARINO, Calif., May 29 /PRNewswire/ -- Epeius Biotechnologies ( http://www.epeiusbiotech.com ) announced today the results of an on-going Phase I/II study of Rexin-G for metastatic bone and soft tissue sarcoma (J Clin Oncol 26: 14509, 2008). Rexin-G is the first and so far only targeted ge...

TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)

SAN MARINO, Calif., May 22 /PRNewswire/ -- Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast cancer that is refractory to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical trial...

Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia

- Data Presented at American Urological Association Annual Meeting - SEATTLE and ORLANDO, Fla., May 21 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN ) today presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small...

Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings

Nektar's Technology Enables First-Ever PEGylation of a Small Molecule with Demonstrated Therapeutic Activity SAN CARLOS, Calif., May 16 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced initial results today from a Phase 1 study of NKTR- 102, PEGylated i...

Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer

Phase II Data Presented at ASCO Showed Acceptable Tolerability Profile, with Low Incidence of Grade 3 and 4 Neuropathy WOODCLIFF LAKE, N.J., May 15 /PRNewswire/ -- The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated pop...

Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research

EAST SETAUKET, N.Y., April 23 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that Dr. Jie Lu and Dr. Zhengping Zhuang of the Surgical Neurology Branch (SNB), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes ...

Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting

SAN FRANCISCO, April 14 /PRNewswire-FirstCall/ -- Positive preclinical data was presented by Nektar Therapeutics (Nasdaq: NKTR ) this week for its lead oncolytic candidate, NKTR-102 (PEG-irinotecan), which demonstrated enhanced anti-tumor activity in a mouse xenograft model of colorectal canc...

Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models

SAN CARLOS, Calif., April 14 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO ) today announced preclinical data demonstrating the mechanism of action and the potent therapeutic activity of NU206 (R-spondin1) in chemotherapy or radiation-induced oral mucositis models. The data were presen...

Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months

Isis Will Host a Conference Call on Monday, April 14, at 8:30 a.m. E.T. at http://www.isispharm.com CARLSBAD, Calif., April 14 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced additional results from its ongoing Phase 2 open-label extensio...

Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007

NEW YORK, April 9, 2008 /PRNewswire/ -- Intra-Cellular Therapies, Inc., today announced additional preclinical data from its ongoing development programs for ITI-007, the Company's first-in-class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM), and ITI-722, a l...

Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722

NEW YORK, April 9, 2008 /PRNewswire/ -- Intra-Cellular Therapies, Inc., today announced additional preclinical data from its ongoing development programs for ITI-007, the Company's first-in-class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM), and ITI-722, a l...

Rigel's R788 Shows Preclinical Activity in Type 1 Diabetes Model

Research To Be Presented at American Association of Immunologists Meeting SOUTH SAN FRANCISCO, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that its oral Syk kinase inhibitor, R788, may be a useful treatment for type 1 diabetes mel...

ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones

FREDERICK, Md., April 1, 2008 /PRNewswire/ -- ImQuest BioSciences, Inc. announced today the publication of the results of an important structure- activity relationship study to investigate the efficacy and toxicity of a series of pyrimidinedione analogs against HIV-1 and HIV-2. The manuscript,...

Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks

Single-Dose, Volunteer fMRI Study Completed and Reported Today Dosing in Four Week Higher Repeat Dose Study Completed HAMBURG, Germany and OXFORD, England, March 28 /PRNewswire-FirstCall/ -- Evotec (Frankfurt Stock Exchange: EVT) is pleased to announce the preliminary findings of ...

Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., March 10 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today announced positive interim data fro...